Kangwo Advanced Manufacturing Secures RMB 15 Million in Angel Funding to Advance Acoustic Field-Based Biomanufacturing Platform

VCBeat has learned that Shenzhen Kangwo Advanced Manufacturing Technology Co., Ltd. (hereinafter referred to as “Kangwo Advanced Manufacturing”), a company dedicated to its “acoustic field bio-manufacturing technology platform,” has successfully completed an angel round of financing worth RMB 15 million. The investor is Jiayou Fund, with Fencun Capital serving as the exclusive financial advisor for this round of financing.

Kanvo Advanced Manufacturing is an innovative technology enterprise that leverages physical acoustic fields as a platform, integrating technologies such as stem cell development, 3D bioprinting, cell encapsulation, and AI-assisted design to manipulate stem cell growth and their integration with materials, thereby synthesizing highly bioactive tissues and organs. The company was co-founded by Professor Chen Pu, who returned from Stanford University and Harvard University in the United States; Mr. Zheng Lixin, who previously held positions at McKinsey & Company, Sino-American SmithKline (SAS), GlaxoSmithKline (GSK), and other major international healthcare corporations; and a team with extensive experience in the field of regenerative medicine. Within less than two years of its establishment, Kanvo successfully developed multiple generations of acoustic field bio-assemblers, along with specialized bio-inks, cell lines, and related consumables. Furthermore, the company has fabricated high-fidelity tissue simulants, including liver lobules, brain organoids, nerve bundles, and cardiac patches. The first-generation acoustic bio-assembler has been procured by several leading biological laboratories, including those at City University of Hong Kong, Sun Yat-sen University, and Wuhan University. Since early 2023, the company has continuously showcased its innovations at major international conferences such as the National Conference on Biofabrication in China, BioHK, and TERMIS, pioneering and leading the development of this novel application of acoustic biofabrication technology.

Professor Chen Pu, Co-founder of KangwoIntroduction: Acoustic bioassembly is an advanced biomanufacturing pathway for the new generation of tissue engineering and regenerative medicine. Compared with traditional manufacturing modes such as additive and subtractive manufacturing, it is an emerging advanced manufacturing mode that assembles tangible cells into functional tissues by leveraging intangible acoustic potential energy fields. Acoustic bioassembly designs the spatial topology of acoustic potential energy fields through acoustic transducers and potential field algorithms, thereby controlling the tissue morphology formed by cell assembly and the spatial distribution of heterogeneous cells. Compared with traditional biomanufacturing technologies such as 3D bioprinting, acoustic bioassembly offers superior cell compatibility, enabling large-scale manipulation and parallel manufacturing of stem cells and primary cells. It also achieves physiologically relevant cell densities and robust cell–cell contact-dependent communication, thereby enhancing tissue function. In addition to harnessing the physical effects of acoustics, Kangwo Advanced Manufacturing is developing acoustic-based bioreactors that leverage the biological effects of acoustics to promote the proliferation and differentiation of rare stem cells and primary cells, thereby serving the cell therapy industry and regenerative medicine. We are committed to establishing Kangwo Advanced Manufacturing as a global leader in acoustic biomanufacturing and a disruptive innovator in regenerative medicine.

Lei Yating, Investor in This RoundIt indicates that the bio-artificial organ industry is building a massive industrial chain comparable to that of the automotive industry. Kangwo has achieved a global first with its fourth-generation acoustic field assembly technology at the highest value point of the industrial chain. Compared with the previous three generations, this technology offers significant advantages and presents a clear second growth curve, positioning it to achieve large-scale commercial application ahead of competitors. The integration of intelligent manufacturing and healthcare represents a composite competition involving resources, technology, teams, and business models, where Kangwo holds inherent advantages. I am highly confident in Kangwo’s future.

Fencun Capital, serving as the financial advisorStatement: Kangwo Advanced Manufacturing’s acoustic field assembly technology is a genuinely original innovation led by Chinese scientists on the global stage. This technology integrates Professor Chen Pu, the company’s co-founder, combining his biological research at Harvard University with his inventions in acoustic wave assembly at Stanford University, and has undergone continuous upgrades and iterations after his return to Wuhan University. Acoustic field bio-assembly is an ultra-efficient, high-throughput cell manipulation technique with extremely low cell damage rates. Based on this technology, highly biomimetic tissue organs capable of performing physiological functions can be assembled for scientific research and clinical applications, yielding promising preliminary results. As a novel non-contact cell manipulation technology, it holds vast potential for diverse application scenarios yet to be explored. In terms of commercial translation, Zheng Lixin (Chairman) and Dr. Zhou Jinsheng (CEO), who have long been engaged in the manufacturing of bio-artificial organs, bring extensive experience in product commercialization and business operations. Within just one year, they successfully led their team in translating the technology into practical applications, exploring multiple use cases, and establishing collaborations with dozens of research institutions. We look forward to Kangwo accelerating the development of further applications following this round of financing, expanding from China to the international market. We are honored to participate in and witness this journey.

A boutique investment bank specializing in the healthcare sector, with team members hailing from leading domestic investment firms, investment banks, and consulting companies. We have successfully facilitated equity financing for numerous healthcare projects spanning medical services, medical devices, pharmaceuticals, and other fields. Rooted in China’s capital markets, our mission is to promote the integration and interaction between industry and capital, enhance industrial operational efficiency, and focus on value discovery and enhancement for high-growth and leading enterprises in the future of healthcare.